[go: up one dir, main page]

WO2009051119A1 - ピリミジルインドリン化合物 - Google Patents

ピリミジルインドリン化合物 Download PDF

Info

Publication number
WO2009051119A1
WO2009051119A1 PCT/JP2008/068607 JP2008068607W WO2009051119A1 WO 2009051119 A1 WO2009051119 A1 WO 2009051119A1 JP 2008068607 W JP2008068607 W JP 2008068607W WO 2009051119 A1 WO2009051119 A1 WO 2009051119A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
indoline compound
pyrimidyl
pyrimidyl indoline
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/068607
Other languages
English (en)
French (fr)
Inventor
Toshio Kaneko
Takeshi Shida
Takayuki Baba
Koji Matsumoto
Kazumasa Aoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0818338 priority Critical patent/BRPI0818338A2/pt
Priority to AU2008312948A priority patent/AU2008312948C1/en
Priority to US12/738,200 priority patent/US8232287B2/en
Priority to EP08840535.2A priority patent/EP2210886B1/en
Priority to MX2010004232A priority patent/MX2010004232A/es
Priority to KR1020107008031A priority patent/KR101536021B1/ko
Priority to CN200880122006.9A priority patent/CN101896481B/zh
Priority to JP2009538098A priority patent/JP5317354B2/ja
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to CA2710182A priority patent/CA2710182C/en
Priority to NZ585284A priority patent/NZ585284A/en
Publication of WO2009051119A1 publication Critical patent/WO2009051119A1/ja
Priority to ZA2010/02552A priority patent/ZA201002552B/en
Priority to IL205057A priority patent/IL205057A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

　従来の経口血糖降下剤の有効成分として使用される化合物とは異なる構造を有し、優れた血糖降下作用を有するピリミジルインドリン系化合物を提供すること。 　一般式（Ｉ）： 【化１】 で表される化合物またはその薬学的に許容され得る塩。
PCT/JP2008/068607 2007-10-16 2008-10-15 ピリミジルインドリン化合物 Ceased WO2009051119A1 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN200880122006.9A CN101896481B (zh) 2007-10-16 2008-10-15 嘧啶基二氢吲哚化合物
US12/738,200 US8232287B2 (en) 2007-10-16 2008-10-15 Pyrimidyl indoline compound
EP08840535.2A EP2210886B1 (en) 2007-10-16 2008-10-15 Pyrimidyl indoline compound
MX2010004232A MX2010004232A (es) 2007-10-16 2008-10-15 Compuesto de indolina de pirimidilo.
KR1020107008031A KR101536021B1 (ko) 2007-10-16 2008-10-15 피리미딜 인돌린 화합물
JP2009538098A JP5317354B2 (ja) 2007-10-16 2008-10-15 ピリミジルインドリン化合物
CA2710182A CA2710182C (en) 2007-10-16 2008-10-15 Pyrimidyl indoline compound
BRPI0818338 BRPI0818338A2 (pt) 2007-10-16 2008-10-15 Composto de pirimidil indolina
AU2008312948A AU2008312948C1 (en) 2007-10-16 2008-10-15 Pyrimidyl indoline compound
NZ585284A NZ585284A (en) 2007-10-16 2008-10-15 Pyrimidyl indoline compounds with hypoglycaemic effect useful in the treatment of diabetes related diseases and adiposity
ZA2010/02552A ZA201002552B (en) 2007-10-16 2010-04-12 Pyrimidyl indoline compound
IL205057A IL205057A0 (en) 2007-10-16 2010-04-13 Pyrimidyl indoline compound, composition comprising the same and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-268937 2007-10-16
JP2007268937 2007-10-16

Publications (1)

Publication Number Publication Date
WO2009051119A1 true WO2009051119A1 (ja) 2009-04-23

Family

ID=40567381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068607 Ceased WO2009051119A1 (ja) 2007-10-16 2008-10-15 ピリミジルインドリン化合物

Country Status (16)

Country Link
US (1) US8232287B2 (ja)
EP (1) EP2210886B1 (ja)
JP (1) JP5317354B2 (ja)
KR (1) KR101536021B1 (ja)
CN (1) CN101896481B (ja)
AU (1) AU2008312948C1 (ja)
BR (1) BRPI0818338A2 (ja)
CA (1) CA2710182C (ja)
IL (1) IL205057A0 (ja)
MX (1) MX2010004232A (ja)
MY (1) MY151295A (ja)
NZ (1) NZ585284A (ja)
RU (1) RU2464269C2 (ja)
TW (1) TWI421074B (ja)
WO (1) WO2009051119A1 (ja)
ZA (1) ZA201002552B (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010095663A1 (ja) * 2009-02-18 2010-08-26 武田薬品工業株式会社 縮合複素環化合物
WO2010149685A1 (en) * 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
WO2011025006A1 (ja) * 2009-08-31 2011-03-03 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
FR2955580A1 (fr) * 2010-01-28 2011-07-29 Sanofi Aventis Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
CN102803258A (zh) * 2010-01-20 2012-11-28 赛诺菲 烷基-杂环氨基甲酸酯衍生物，它们的制备和治疗应用
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013108800A1 (ja) 2012-01-18 2013-07-25 第一三共株式会社 置換フェニルアゾール誘導体
US8609676B2 (en) * 2009-08-04 2013-12-17 Merck Sharp & Dohme, Corp. 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
US8765771B2 (en) 2010-06-25 2014-07-01 Kowa Co., Ltd. Condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
WO2014156196A1 (ja) * 2013-03-29 2014-10-02 一般社団法人ファルマバレープロジェクト支援機構 ２型糖尿病治療剤
WO2020145250A1 (ja) * 2019-01-08 2020-07-16 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759843A1 (en) * 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
WO2010128414A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
JP2013511571A (ja) * 2009-11-23 2013-04-04 ファイザー・インク Ｇｐｒ１１９阻害剤としてのイミダゾ−ピラゾール
US8785463B2 (en) * 2010-10-08 2014-07-22 Cadila Healthcare Limited GPR 119 agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515602A (ja) * 1999-11-30 2003-05-07 ファイザー・プロダクツ・インク 免疫抑制薬として有用な２，４−ジアミノピリミジン化合物
WO2005007647A1 (en) * 2003-07-11 2005-01-27 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006083491A2 (en) * 2005-01-10 2006-08-10 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US7101869B2 (en) * 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
JP4592417B2 (ja) 2002-06-19 2010-12-01 プロキシマゲン・リミテッド 新規方法
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
UA86943C2 (ru) * 2003-07-11 2009-06-10 Арена Фармасьютикалз, Инк. Тризамещенные производные арилов и гетероарилов как модуляторы метаболизма и профилактика и лечение связанных с ними нарушений
FR2866884B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
WO2008008887A2 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for treating metabolic disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515602A (ja) * 1999-11-30 2003-05-07 ファイザー・プロダクツ・インク 免疫抑制薬として有用な２，４−ジアミノピリミジン化合物
WO2005007647A1 (en) * 2003-07-11 2005-01-27 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006083491A2 (en) * 2005-01-10 2006-08-10 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2210886A4 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010095663A1 (ja) * 2009-02-18 2010-08-26 武田薬品工業株式会社 縮合複素環化合物
JP5657518B2 (ja) * 2009-02-18 2015-01-21 武田薬品工業株式会社 縮合複素環化合物
US8410089B2 (en) 2009-02-18 2013-04-02 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
JP2012530758A (ja) * 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2010149685A1 (en) * 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8609676B2 (en) * 2009-08-04 2013-12-17 Merck Sharp & Dohme, Corp. 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
WO2011025006A1 (ja) * 2009-08-31 2011-03-03 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
CN102803258B (zh) * 2010-01-20 2016-04-20 赛诺菲 烷基-杂环氨基甲酸酯衍生物，它们的制备和治疗应用
CN102803258A (zh) * 2010-01-20 2012-11-28 赛诺菲 烷基-杂环氨基甲酸酯衍生物，它们的制备和治疗应用
US9000010B2 (en) 2010-01-20 2015-04-07 Sanofi Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
FR2955580A1 (fr) * 2010-01-28 2011-07-29 Sanofi Aventis Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique
US8765771B2 (en) 2010-06-25 2014-07-01 Kowa Co., Ltd. Condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013108800A1 (ja) 2012-01-18 2013-07-25 第一三共株式会社 置換フェニルアゾール誘導体
US9725438B2 (en) 2012-01-18 2017-08-08 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
US9233958B2 (en) 2012-01-18 2016-01-12 Daiichi Sankyo Company, Limited Substituted phenylazole derivatives
EP3009433A1 (en) 2012-01-18 2016-04-20 Daiichi Sankyo Company, Limited 2-phenyl-1,3-oxazole and 5-phenyl-1,2,4-oxadiazole derivatives for the treatment of diabetes
JPWO2014156196A1 (ja) * 2013-03-29 2017-02-16 国立大学法人 熊本大学 ２型糖尿病治療剤
WO2014156196A1 (ja) * 2013-03-29 2014-10-02 一般社団法人ファルマバレープロジェクト支援機構 ２型糖尿病治療剤
WO2020145250A1 (ja) * 2019-01-08 2020-07-16 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬
CN113226310A (zh) * 2019-01-08 2021-08-06 杏林制药株式会社 15-pgdh抑制剂
JPWO2020145250A1 (ja) * 2019-01-08 2021-11-18 杏林製薬株式会社 １５−ｐｇｄｈ阻害薬
US20230082516A1 (en) * 2019-01-08 2023-03-16 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitor
JP7575952B2 (ja) 2019-01-08 2024-10-30 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬
IL283608B1 (en) * 2019-01-08 2025-02-01 Kyorin Pharmaceutical Co Ltd Co Number 0100 01 01479 15-PGDH inhibitor
IL283608B2 (en) * 2019-01-08 2025-06-01 Kyorin Pharmaceutical Co Ltd Co Number 0100 01 01479 15-PGDH inhibitor
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors

Also Published As

Publication number Publication date
US20100292259A1 (en) 2010-11-18
US8232287B2 (en) 2012-07-31
RU2464269C2 (ru) 2012-10-20
RU2010119487A (ru) 2011-11-27
KR20100071068A (ko) 2010-06-28
IL205057A0 (en) 2010-11-30
KR101536021B1 (ko) 2015-07-10
CN101896481B (zh) 2014-04-30
ZA201002552B (en) 2011-10-26
AU2008312948C1 (en) 2012-08-09
TW200922588A (en) 2009-06-01
MY151295A (en) 2014-04-30
CA2710182C (en) 2012-08-14
AU2008312948B2 (en) 2012-03-01
BRPI0818338A2 (pt) 2015-04-22
NZ585284A (en) 2011-03-31
CA2710182A1 (en) 2009-04-23
EP2210886A4 (en) 2011-08-17
TWI421074B (zh) 2014-01-01
JP5317354B2 (ja) 2013-10-16
EP2210886A1 (en) 2010-07-28
MX2010004232A (es) 2010-09-30
AU2008312948A1 (en) 2009-04-23
JPWO2009051119A1 (ja) 2011-03-03
CN101896481A (zh) 2010-11-24
EP2210886B1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2007135527A3 (en) Benzimidazolyl compounds
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2011012816A3 (fr) Formulation pharmaceutique
WO2007117465A3 (en) Indazole compounds
TW200728307A (en) Novel spirochromanone derivatives
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2008096001A8 (en) Hcv inhibiting macrocyclic phenylcarbamates
WO2008136392A1 (ja) 経口投与用製剤
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2009060952A1 (ja) 新規製剤
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2007092157A9 (en) 7-(1h-imidazol-4-yl) methyl) -5,6,7,8-tetrahydroquinoline
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2009096667A3 (ko) 신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880122006.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08840535

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009538098

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008840535

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107008031

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 205057

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2710182

Country of ref document: CA

Ref document number: 12010500817

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2636/DELNP/2010

Country of ref document: IN

Ref document number: MX/A/2010/004232

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008312948

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 585284

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 10058225

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2010119487

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008312948

Country of ref document: AU

Date of ref document: 20081015

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010001724

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12738200

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0818338

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100415